The p38 MAPK inhibitor SB203580 blocks adenosine A1 receptor-induced attenuation of in vivo myocardial stunning

Cardiovascular Drugs and Therapy

Volumn 18, Issue 6, 2004, Pages 433-440

  Yoshimura, Yukihiro ^a   Kristo, Gentian ^a   Keith, Byron J ^a   Jahania, Salik A ^a   Mentzer Jr , Robert M ^a   Lasley, Robert D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adenosine receptors; Ischemia reperfusion injury; Myocardial stunning; p38 mitogen activated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ADENOSINE A1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PRELOAD; HEART PROTECTION; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; STUNNED HEART MUSCLE; SWINE;

ANIMALS; BLOOD PRESSURE; CORONARY VESSELS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; IMIDAZOLES; MALE; MYOCARDIAL STUNNING; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, ADENOSINE A1; SWINE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 16844385112     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-004-6220-4     Document Type: Article

References (44)

1. Braunward E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
2. Randhawa MP, Lasley RD, Mentzer RM Jr. Salutary effects of exogenous adenosine administration on in vivo myocardial stunning. J Thorac Cardiovasc Surg 1995;110:63-74.
3. Sekili S, Jeroudi MO, Tang XL, Zughaib M, Sun JZ, Bolli R. Effect of adenosine on myocardial 'stunning' in the dog. Circ Res 1995;76:82-94.
4. Ogawa T, Miura T, Shimamoto K, Iimura O. Activation of adenosine receptors before ischemia enhances tolerance against myocardial stunning in the rabbit heart. J Am Coll Cardiol 1996;27:225-233.
5. Lasley RD, Zhou Z, Hegge JO, Bunger R, Mentzer RM Jr. Adenosine attenuates in vivo myocardial stunning with minimal effects on cardiac energetics. Basic Res Cardiol 1998;93:303-312.
6. Lasley RD. The protective effects of adenosine in reversibly and irreversibly injured ischemic myocardium. In: Pelleg A, Austin BL, eds. Effects of Extracellular Adenosine and ATP on Cardiomyocytes. Texas: Landes, 1998:133-172.
7. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovasc Res 2001;52:25-39.
8. 1 receptor-mediated cardioprotection in stunned canine myocardium. Circulation 1993;88:235-244.
9. 1 adenosine receptor. Basic Res Cardiol 2001;96:487-496.
10. 2A receptor agonist AMP579 induces both acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol (Heart Circ Physiol) 2004;287:H2746-H753.
11. Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: A role in cardiac myocyte hypertrophy? J Cell Biol 1998;142:523-535.
12. Haq SE, Clerk A, Sugden PH. Activation of mitogen-activated protein kinases (p38 MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart. FEBS Lett 1998;434:305-308.
13. Lazou A, Sugden PH, Clerk A. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPK/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem, J 1998;332(Pt 2):459-465.
14. Markou T, Lazou A. Phosphorylation and activation of mitogen- and stress-activated protein kinase-1 in adult rat cardiac myocytes by G-protein-coupled receptor agonists required both extracellular-signal-regulated kinase and p38 mitogen-activated protein kinase. Biochem J 2002;365:757-763.
15. Clerk A, Michael A, Sugden PH. Stimulation of multiple mitogen-activated protein kinase sub-families by oxidative stress and phosphorylation of the small heat shock protein, HSP25/27, in neonatal ventricular myocytes. Biochem J 1998;333:581-589.
16. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/ERK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996;79:162-173.
17. Yue TL, Wang C, Gu JL, et al. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000;86:626-629.
18. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 2002;97:276-285.
19. Gorog DA, Tanno M, Cao X, et al. Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia. Cardiovasc Res 2004;61:123-131.
20. Glower DD, Spratt JA, Snow ND, et al. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable work. Circulation 1985;71:994-1009.
21. Glower DD, Spratt JA, Kabas JS, Davis JW, Rankin JS. Quantification of regional myocardial dysfunction after acute ischemic injury. Am J Physiol 1988;255:H85-H93.
22. Jahania MS, Lasley RD, Mentzer RM Jr. Ischemic preconditioning does not acutely improve load-insensitive parameters of contractility in in vivo stunned porcine myocardium. J Thorac Cardiovasc Surg 1999;117:810-817.
23. Lasley RD, Jahania MS, Mentzer RMJr. Beneficial effects of adenosine A(2a) agonist CGS-21680 in infracted and stunned porcine myocardium. Am J Physiol (Heart Circ Physiol) 2001;280:H1660-H1666.
24. Stevens RM, Jahania MS, Mentzer RM Jr, Lasley RD. Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardium stunning. Ann Thorac Surg 2004;77:651-657.
25. Kristo G, Yoshimura Y, Niu J, et al. The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in in vivo porcine myocardium. Am J Physiol (Heart Circ Physiol) 2004;286:H517-H524.
26. 2 receptor agonist AMP579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 1998;286:611-618.
27. Xu Z, Yang XM, Cohen MV, Neumann T, Heusch G, Downey JM. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP579 administered at reperfusion. J Mol Cell Cardiol 2000;32:2339-2347.
28. Xu Z, Jiao Z, Cohen MV, Downey JM. Protection from AMP579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. J Cardiovasc Pharmacol 2002;40:510-518.
29. 2A receptor and Erk1/2. Cardiovasc Drugs Ther 2003;17:415-425.
30. Budde JM, Velez DA, Zhao Z, et al. Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res 2000;47:294-305.
31. Kristo G, Yoshimura Y, Ferraris SP, Jahania MS, Mentzer RM Jr, Lasley RD. The preischemic combination of the sodium-hydrogen exchange inhibitor cariporide and the adenosine agonist AM579 acts additively to reduce myocardial infarct size. JAm Col Surg 2004;199:586-594.
32. Robinson AJ, Dickenson JM. Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells. Eur J Pharmacol 2001;413:151-161.
33. 1 receptors in cardiomyocytes: Role for p38 MAPK. Am. J Physiol (Heart Circ Physiol) 2003;285:H97-H103.
34. Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A(1) receptor induced delayed preconditioning in rabbits: Induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. Circ Res 2000;86:989-997.
35. Zhao TC, Hines DS, Kukreja RC. Adenosine-induced late preconditioning in mouse hearts: Role of p38 MAP kinase and mitochondrial K(ATP) channels. Am J Physiol (Heart Circ Physiol) 2001;280:H1278-H1285.
36. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-1691.
37. Marais E, Genade S, Strijdom H, Moolman JA, Lochner A. p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischemic preconditioning. J Mol Cell Cardiol 2001;33:2157-2177.
38. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol 2001;33:769-778.
39. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 2001;88:175-180.
40. Schulz R, Belosjorow S, Gres P, Jansen J, Michel MC, Heusch G. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 2002;55:690-700.
41. Ping P, Zhang J, Huang S, et al. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. Am J Physiol (Heart Circ Physiol) 1999;277:H1771-H1785.
42. 1 receptor preconditioning in rat myocardium. Am J Physiol (Heart Circ Physiol) 2005; first published online Nov. 11, 2004.
43. Fryer RM, Patel HH, Hsu AK, Gross GJ. Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am J Physiol (Heart Circ Physiol) 2001;281:H1184-H1192.
44. Clerk A, Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress- activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 1998;426:93-96.